Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.44 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404802 | 0.88 | ALDH1A1 (0.52) | ALDH1A1HPGDHSD17B10KDM4EMEN1 | |
| SCHEMBL10935027 | 0.88 | ALDH1A1 (0.52) | ALDH1A1HPGDHSD17B10KDM4EMEN1 | |
| SCHEMBL4799007 | 0.87 | ALDH1A1 (0.50) | ALDH1A1HPGDHSD17B10KDM4EMEN1 | |
| SCHEMBL30393029 | 0.85 | ALDH1A1 (0.61) | ALDH1A1HPGDHSD17B10KDM4EMEN1 | |
| SCHEMBL503962 | 0.85 | ALDH1A1 (0.61) | ALDH1A1HPGDHSD17B10KDM4EMEN1 | |
| SCHEMBL6562825 | 0.85 | ALDH1A1 (0.66) | ALDH1A1HPGDHSD17B10KDM4EMEN1 | |
| SCHEMBL4345297 | 0.84 | NPC1 (0.60) | ALDH1A1HPGDHSD17B10KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL1037379 | 0.84 | ALDH1A1 (0.60) | ALDH1A1HSD17B10KDM4ECTSDRAB9A | |
| SCHEMBL8484523 | 0.84 | IDO1 (0.49) | ALDH1A1HPGDHSD17B10KDM4EMEN1 | |
| SCHEMBL27357244 | 0.83 | ALDH1A1 (0.53) | ALDH1A1HPGDHSD17B10KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947351-A2 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF | Board of Regents, The University of Texas System (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020205646-A2 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2018195263-A1 | METHODS FOR THE TREATMENT OF CANCER METASTASIS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-10-25 | — | — | WO | disclosed |
| EP-3271017-A1 | TREATMENT OF SKIN CONDITIONS | Monash University (AU) | 2018-01-24 | — | — | EP | disclosed |
| WO-2017184752-A1 | ANTI-FUNGAL COMPOUNDS | SAINT LOUIS UNIVERSITY (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017165170-A1 | ELECTRON WITHDRAWING GROUP SUBSTITUTED AND MACROCYCLIC PGJ3 ANALOGS AND METHODS OF TREATMENT THEREOF | WILLIAM MARSH RICE UNIVERSITY (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20170273954-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2017-09-28 | — | — | US | disclosed |
| US-9675592-B2 | Methods and compositions for bacteria infections | THE UNIVERSITY OF CHICAGO (US) | 2017-06-13 | — | — | US | disclosed |
| EP-3169683-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen Ltd. (AU) | 2017-05-24 | — | — | EP | disclosed |
| WO-2017044592-A1 | CONJUGATED ANTICANCER SMAC ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2012083306-A2 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011130302-A2 | METHOD OF TREATING OBESITY USING ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011124986-A2 | POLYOL MODIFIED AMINOGLYCOSIDE-LIPID CONJUGATES | UNIVERSITY OF MANITOBA (CA) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011115819-A2 | SMALL MOLECULE INHIBITORS OF MUC1 AND METHODS OF IDENTIFYING THE SAME | GENUS ONCOLOGY, LLC (US) | 2011-09-22 | — | — | WO | disclosed |
| CN-101878217-A | Agent for prevention and/or treatment of skin diseases | KYOWA HAKKO KIRIN CO LTD | 2010-11-03 | — | — | CN | disclosed |
| US-7132414-B2 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | AVENTIS PHARMA S.A. (FR) | 2006-11-07 | — | — | US | disclosed |
| US-20040157823-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | AVENTIS PHARMA S.A. (FR) | 2004-08-12 | — | — | US | disclosed |
| US-6734176-B2 | ARE CB1-RECEPTOR ANTAGONISTS AND ARE USEFUL IN THE TREATMENT AND PREVENTION OF DISORDERS AFFECTING THE CENTRAL NERVOUS, IMMUNE, CARDIOVASCULAR OR ENDOCRINE, RESPIRATORY, GASTROINTESTINAL AND REPRODUCTIVE SYSTEMS; DRUG ABUSE | AVENTIS PHARMA S.A. (FR) | 2004-05-11 | — | — | US | disclosed |
| US-20030119810-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | AVENTIS PHARMA S.A. (FR) | 2003-06-26 | — | — | US | disclosed |
| US-20020019383-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273954-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | SPOUT1, OXA1L, VSIR | ALDH1A1 2647/4885HPGD 3089/4885HSD17B10 3941/4885 |
| US-20020019383-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | HRH2, ALK, HRH1 | ALDH1A1 1211/4885HPGD 499/4885HSD17B10 1357/4885 |
| US-20040157823-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | ALK, HRH2, HRH1 | ALDH1A1 1049/4885HPGD 429/4885HSD17B10 1217/4885 |
| US-20030119810-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | ALK, HRH2, HRH1 | ALDH1A1 1049/4885HPGD 429/4885HSD17B10 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.